H.C. Wainwright raised the firm’s price target on Fulcrum Therapeutics to $17 from $14 and keeps a Buy rating on the shares. The analyst believes Fulcrum has learned from prior studies and remains cautiously optimistic on REACH hitting the primary end point.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on FULC:
- Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
- Fulcrum Therapeutics (FULC) Q4 Earnings Cheat Sheet
- Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
- Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
